Israel’s NeoTX (see here previously) is now conducting a Phase 2 trial of its naptumomab estafenatox (NAP) bacteria-coated, immunotherapy cancer treatment on 30 patients in the US. It is also enhancing an AstraZeneca checkpoint inhibitor. NeoTX has 3 Nobel prizewinners in its team.
https://www.israel21c.org/new-cancer-treatment-fools-the-immune-system-to-attack/
https://finance.yahoo.com/news/neotx-announces-successful-first-stage-120000979.html